AB Science S.A. (LON:0Q77)

Market Cap	71.85M
Revenue (ttm)	917.34K
Net Income (ttm)	-5.12M
Shares Out	n/a
EPS (ttm)	-0.10
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18
Average Volume	698
Open	1.414
Previous Close	1.388
Day's Range	1.338 - 1.414
52-Week Range	1.412 - 6.680
Beta	1.46
RSI	38.31
Earnings Date	Apr 30, 2025

About AB Science

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company’s lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer’s disease, ...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 2001
• Employees: 57
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0Q77

Financial Performance

In 2023, AB Science's revenue was 970,000, an increase of 1.25% compared to the previous year's 958,000. Losses were -11.99 million, -11.97% less than in 2022.

Financial numbers in EUR